IXICO to support clinical trial for Parkinson’s drug OXB 102

The study, which is anticipated to commence by the middle of this year, will see IXICO support the use of novel brain scanning techniques in a phase I/II trial to test the experimental Parkinson’s drug, OXB-102.

IXICO will be involved in the trials for about five years including follow up trials in the long term. It will oversee the use of novel radiopharmaceutical ligands at specialist imaging centers across Europe.

IXICO has also entered into a consortium with a series of major pharmaceutical companies on treating Parkinson’s Disease.

The company joined seven pharmaceutical companies, including AbbVie, AstraZeneca, Biogen, Eli Lilly and Company, Merck Sharp & Dohme, Pfizer, and UCB in the Critical Path for Parkinson’s Consortium, formed by Parkinson’s UK and the Critical Path Institute.

The consortium intends to standardize clinical trials, share data and bring together researchers to develop safe and effective therapies for Parkinson’s disease.

IXICO CEO Derek Hill said: "This is a time of great innovation in the design of clinical trials of new treatments for Parkinson’s disease.

"It is a privilege to be joining these major global pharmaceutical companies and Parkinson’s UK in the Critical Path Institute’s CPP consortium and to work together to accelerate progress in developing new therapies for Parkinson’s disease patients."